Trevi Therapeutics reports Q3 EPS (8c), consensus (9c)

Ended Q3 with $88.9M in cash, cash equivalents and marketable securities. “We are thrilled to have initiated our Phase 2a RIVER trial of Haduvio in patients with refractory chronic cough, which builds on the strength of the clinical data seen with Haduvio in IPF chronic cough,” said Jennifer Good, CEO. “Refractory chronic cough impacts up to 10% of the adult population globally. We believe Haduvio is well-positioned in IPF chronic cough, as well as in RCC, based on its ability to target cough centrally and peripherally which potentially supports the ability to work across a wide range of cough conditions.”